MAPK
Les MAPK sont une famille de kinases protéiques impliquées dans une variété de processus cellulaires, y compris la croissance, la prolifération, la différenciation et les réponses au stress. La voie de signalisation MAPK comprend plusieurs niveaux, y compris ERK, JNK et p38 MAPK, chacun jouant des rôles distincts dans la fonction cellulaire. La dérégulation de la signalisation MAPK est liée au cancer, aux maladies inflammatoires et aux troubles métaboliques. Chez CymitQuimica, nous offrons un large éventail d'inhibiteurs et d'activateurs de MAPK pour soutenir vos recherches en biologie cellulaire, transduction de signaux et mécanismes des maladies.
893 produits trouvés pour "MAPK". Les 500 premiers sont affichés.
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
HPK1-IN-4
CAS :HPK1-IN-4 is an HPK1 (MAPK41) inhibitor with an IC 50 of 0.061 nM. HPK1-IN-4 is often used as a preclinical immunotherapy tool compound.Formule :C23H26N6O3Degré de pureté :97.06%Couleur et forme :Yellow SolidMasse moléculaire :434.49Ref: TM-T40350
1mg123,00€5mg295,00€1mL*10mM (DMSO)326,00€10mg447,00€25mg782,00€50mg1.071,00€100mg1.468,00€SIAIS562055
SIAIS562055, a potent cereblon-based SOS1PROTAC, exhibits a dissociation constant (Kd) of 95.9 nM. It effectively degrades SOS1 and inhibits the downstream ERK pathway. SIAIS562055 disrupts the interaction between KRASG12C or KRASG12D and SOS1, with IC50 values of 95.7 nM and 134.5 nM, respectively. This compound demonstrates strong anticancer activity.Formule :C49H62F3N7O5SCouleur et forme :SolidMasse moléculaire :918.12MAP4K4-IN-6
MAP4K4-IN-6 (Compound 15f) is a MAP4K4 inhibitor with an IC50 of 80 nM. It reduces the phosphorylation of c-Jun and exhibits neuroprotective effects. Additionally, MAP4K4-IN-6 enhances the vitality of motor neurons and can be utilized in the study of amyotrophic lateral sclerosis (ALS).Couleur et forme :Odour SolidKlotho-derived peptide 1 hydrochloride
Klotho-derived peptide 1 (KP1 human) hydrochloride inhibits the interaction between TGF-β and TGF-β receptor 2, suppressing the activation of TGF-β-induced Smad2/3 and mitogen-activated protein kinase (MAPK). Additionally, it exhibits antifibrotic and renal protective effects in mouse models.Couleur et forme :Odour SolidASP6918
ASP6918 is a potent, orally active KRAS G12C inhibitor with an IC50 of 0.028 µM. It inhibits cell growth and demonstrates antitumor activity.Formule :C36H43N7O3Couleur et forme :SolidMasse moléculaire :621.34274NecroX-2
CAS :NecroX-2 is a cell-permeable necrosis inhibitor with antioxidant properties. NecroX-2 selectively suppresses necrotic cell death triggered by oxidative stress. NecroX-2 does not confer protection against apoptosis induced by staurosporine or etoposide but shows protective effects under conditions such as cold shock, hypoxia, and oxidative stress in vitro.Formule :C25H32N4O4S2Degré de pureté :97.12%Couleur et forme :SolidMasse moléculaire :516.68Antimicrobial agent-21
CAS :Antimicrobial agent-21 is a potent mitogen activated protein kinase inhibitor with antibacterial, anti-inflammatory and antitumor activity for the treatment ofFormule :C18H13N3OSDegré de pureté :99.82%Couleur et forme :SolidMasse moléculaire :319.38Ref: TM-T67942
1mg54,00€5mg116,00€10mg172,00€1mL*10mM (DMSO)180,00€25mg278,00€50mg371,00€100mg510,00€200mg687,00€HPK1-IN-8
CAS :HPK1-IN-8 is an allosteric, inactive, conformation-selective triazolopyrimidine ketone HPK1 inhibitor.Formule :C19H17FN6O2SDegré de pureté :99.68%Couleur et forme :SolidMasse moléculaire :412.44AM-001
CAS :AM-001, a non-competitive inhibitor of Epac1, effectively blocks the activation of Rap1, a downstream effector of Epac1, in cultured cells, and is commonly used in heart disease-related research.Formule :C24H16FN3OS2Degré de pureté :99.92%Couleur et forme :Yellow SolidMasse moléculaire :445.53KRAS G12D inhibitor 6
CAS :KRAS G12D inhibitor 6 is an efficacious compound that effectively inhibits KRAS G12D.Formule :C32H37ClN8O2Couleur et forme :SolidMasse moléculaire :601.15MRTX1133 formic
MRTX1133: Selective inhibitor of KRAS G12D, effective in all protein states, targeting mutant cells.Formule :C34H33F3N6O4Couleur et forme :SoildMasse moléculaire :646.67Mitogen-activated protein kinase 1
CAS :Mitogen-activated protein kinase 1 (MAPK1) activates the p38/NF-κB pathway and regulates cellular processes in sepsis-associated diseases.Degré de pureté :98%Couleur et forme :SolidKRASG12C IN-14
KRASG12C IN-14 (compound 15), a potent inhibitor specifically designed for the KRAS G12C mutation, exhibits impressive efficacy in impeding CYPA-dependent KRAS-BRAF interaction and ERK phosphorylation in NCI-H358 cells, both with an IC 50 of 0.002 μM.Formule :C51H65F4N9O9S2Couleur et forme :SolidMasse moléculaire :1088.24KRAS G12C inhibitor 18
CAS :KRAS G12C inhibitor 18 is a potent, orally active compound that inhibits KRAS G12C and exhibits anti-tumor activities.Formule :C25H20ClFN4O3SCouleur et forme :SolidMasse moléculaire :510.97MRTF-A-IN-1
MRTF-A-IN-1 (compound 14) is an inhibitor of MRTF-A. It effectively suppresses cell proliferation and induces senescence in HCC cells.Formule :C22H21N3Couleur et forme :SolidMasse moléculaire :327.42LYMTAC-2
LYMTAC-2 is a lysosome-targeting chimera (LYMTAC) developed to degrade membrane-associated proteins through lysosomal membrane proteins (LMP) such as RNF152, LAPTM4a, and LAPTM5. It forms a ternary complex with target proteins like KRASG12D, facilitating their relocation to lysosomes and resulting in ubiquitin-dependent degradation. This compound has potential for studying membrane protein regulation and devising strategies to counter resistance in KRAS-driven signaling pathways.Couleur et forme :SolidMasse moléculaire :1248.44JNK3 inhibitor-8
JNK3 inhibitor-8: potent, selective, oral, BBB-penetrating, IC50: JNK3=21 nM, JNK2=2203 nM, JNK1>10,000 nM; potential in Alzheimer's research.Formule :C32H30FN7O3Couleur et forme :SolidMasse moléculaire :579.62BI-2865
CAS :BI-2865 is a non-covalent pan-KRAS inhibitor.Cost-effective and quality-assured.Formule :C23H27N7O2SDegré de pureté :99.29% - 99.92%Couleur et forme :SoildMasse moléculaire :465.57Ref: TM-T72062
1mg200,00€5mg432,00€1mL*10mM (DMSO)440,00€10mg612,00€25mg888,00€50mg1.224,00€100mg1.665,00€SS47
CAS :SS47 is a PROTAC that degrades immunosuppressive HPK1 via proteasome; boosts BCMA CAR-T cell cancer therapy.Formule :C49H56N6O12SCouleur et forme :SolidMasse moléculaire :953.07TUS-007
CAS :TUS-007, a non-proteasome inhibiting CANDDY, is an oral KRAS G12D/V degrader for cell-free chemical knockdown and tumor suppression.Formule :C44H54Cl2N8O5Couleur et forme :SolidMasse moléculaire :845.86LC 2 Epimer
CAS :Negative control for LC 2.Formule :C59H71ClFN11O7SCouleur et forme :SolidMasse moléculaire :1132.8GNE-9815
CAS :GNE-9815 (3-(2-cyanopropan-2-yl)-N-[2-fluoro-4-methyl-5-(7-methyl-8-oxo-7,8-dihydropyrido[2,3-d]pyridazin-3-yl)phenyl]benzamide) is a high kinase-selectiveFormule :C26H22FN5O2Degré de pureté :99.08% - 99.1%Couleur et forme :SolidMasse moléculaire :455.48Ref: TM-T9585
1mg60,00€5mg138,00€1mL*10mM (DMSO)138,00€10mg215,00€25mg358,00€50mg510,00€100mg692,00€500mg1.386,00€Fluconazole-PEG6-XMU-MP-9
Fluconazole-PEG6-XMU-MP-9, PEG-linked conjugate, fluconazole antifungal plus XMU-MP-9, promotes Nedd4-1 mediated K-Ras mutant degradation.Formule :C48H53F3N10O10SDegré de pureté :98.73%Masse moléculaire :1019.06FAM49B (190-198) mouse
CAS :FAM49B (190-198) mouse represents a peptide fragment of the mitochondria-localized protein FAM49B, which is instrumental in regulating mitochondrial fission, function, and integrity, in addition to influencing tumor progression. Beyond its role in mitochondrial dynamics, FAM49B serves as a negative regulator of T cell activation by inhibiting GTPase Rac activity and affecting cytoskeleton reorganization.Formule :C49H71N9O14SCouleur et forme :SolidMasse moléculaire :1042.2KRAS G12C inhibitor 60
KRAS G12C Inhibitor 60 (compound 23), a selective inhibitor targeting the Kras-G12C mutation, is utilized in the investigation of lung, colorectal, andFormule :C31H30F5N7O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :627.61SOS1-IN-17
SOS1-IN-17 (Compound 8d) is an orally active inhibitor targeting the SOS1-KRASG12C interaction, with an IC50 of 5.1 nM. It suppresses ERK phosphorylation in DLD-1 cells with an IC50 of 18 nM and demonstrates antiproliferative activity in KRASG12C-mutant Mia-Paca-2 cells, with an IC50 of 0.11 μM. In mouse models, SOS1-IN-17 shows antitumor efficacy against pancreatic cancer.Formule :C29H34F3N5O2Couleur et forme :SolidMasse moléculaire :541.61PROTAC SOS1 degrader-2
CAS :PROTAC SOS1 degrader-2 reduces pERK & RAS-GTP, inhibiting tumor growth dose-dependently in vivo.Formule :C57H76ClFN10O4SCouleur et forme :SolidMasse moléculaire :1051.79KRAS G12D inhibitor 5
CAS :KRAS G12D inhibitor 5 is a KRAS G12D inhibitor for the potential treatment of pancreatic cancer.Formule :C31H31ClF2N6O2Couleur et forme :SolidMasse moléculaire :593.08PROTAC K-Ras Degrader-1
CAS :PROTAC K-Ras Degrader-1 is a PROTAC degrader based on the Cereblon E3 ligase ligand, capable of degrading K-Ras.Formule :C53H62N10O10Degré de pureté :98.05%Couleur et forme :SolidMasse moléculaire :999.12SHP2-IN-38
SHP2-IN-38 is an innovative green fluorescent inhibitor targeting SHP2, exhibiting IC50 values as follows: 2.89 μM (SHP2), 8.73 μM (SHP1), 11.08 μM (PTP1B), and 33.07 μM (TCPTP). It impedes the SHP2-mediated ERK signaling pathway and inhibits MV4-11 cell proliferation in vitro with an IC50 of 7.90 μM. The excitation wavelength of SHP2-IN-38 is 360 nm, with a maximum emission wavelength of 550 nm in DMSO and 540 nm in DMF. Additionally, it demonstrates green fluorescent imaging in HeLa cells and zebrafish.Couleur et forme :Odour SolidRM-018
CAS :RM-018 inhibits active KRAS G12C & G12C/Y96D, possibly beating resistance with unique traits.Formule :C56H72N8O8Couleur et forme :SolidMasse moléculaire :985.24Pan-RAS-IN-7
CAS :Pan-RAS-IN-7 (Compound D101) is a broad-spectrum RAS inhibitor used in the synthesis of antibody-drug conjugates (ADCs). It is also applicable in cancer research.Formule :C59H76N8O8Couleur et forme :SolidMasse moléculaire :1025.28PROTAC SOS1 degrader-1
CAS :PROTAC SOS1 degrader-1: potent, DC50 98.4 nM, inhibits KRAS mutant cancer cells, low-toxic antitumor.Formule :C57H76O4ClFN10SCouleur et forme :SolidMasse moléculaire :1050.5444312-Oxo phytodienoic acid
CAS :12-oxo PDA boosts alkaloid production in E. californica, enhances B. dioica tendril curls, and blocks JA-induced cell death in A. fru mutants.Formule :C18H28O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :292.41TAT-PAK18 R192A
TAT-PAK18 R192A is an inactive Tat-Pak peptide. It does not influence Rac1 translocation triggered by any tested proteins.Formule :C143H247N55O37Masse moléculaire :3326.91369MEK1/2-IN-3
MEK1/2-IN-3 (Compound M15) is an inhibitor of MEK1, with an IC50 value of 10.29 nM. It effectively suppresses tumor cell proliferation and migration, induces apoptosis, and exhibits good liver microsomal stability. MEK1/2-IN-3 is applicable in the study of solid tumors.Formule :C28H23F3IN3O4Couleur et forme :SolidMasse moléculaire :649.4CC-401
CAS :CC-401 is a specific inhibitor of JNK (Ki: 25-50nM).Formule :C22H24N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :388.47KRAS-IN-43
KRAS-IN-43 (Compound 9) is a broad-spectrum KRAS inhibitor with IC50 values of 0.15 μM for KRASG12V, 0.14 μM for KRASG12C, and 0.47 μM for wild-type KRAS. It disrupts the interaction between KRAS and cRAF and suppresses ERK phosphorylation. KRAS-IN-43 shows potential for research in KRAS mutation-associated cancers, including pancreatic, colorectal, and lung cancers.Couleur et forme :Odour SolidR18
CAS :14.3.3 protein antagonist, blocks binding to Raf-1/Bad/ASK1/exoenzyme S, competitive, no phosphorylation needed, KD ~80 nM.Formule :C101H157N27O29S3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :2309.69PROTAC MEK1 Degrader-1
CAS :PROTAC MEK1 Degrader-1, a targeted protein degradation agent, combines a MEK1 inhibitor with a von Hippel-Lindau ligand to effectively inhibit ERK1/2Formule :C53H66FIN8O11S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1201.17DS03090629
DS03090629, an orally active MEK inhibitor, functions by competitively inhibiting MEK activity in the presence of ATP. This compound demonstrates strong binding affinity to both MEK and phosphorylated MEK, with dissociation constants (Kd) of 0.11 and 0.15 nM, respectively. It has shown efficacy in suppressing the proliferation of melanoma cell lines that overexpress BRAF mutations, achieving IC50 values of 74.3 and 97.8 nM for BRAF V600E and MEK1 F53L transfected A375 cells, respectively. DS03090629 is thus considered promising for anti-melanoma therapies.Formule :C25H26ClN5O2Couleur et forme :SolidMasse moléculaire :463.96BI1701963
BI1701963 is an orally effective inhibitor that targets the SOS1 and KRAS interaction, specifically inhibiting the activation of KRAS by blocking its GTP loading. This compound is utilized in cancer research to explore potential therapeutic effects against KRAS-driven malignancies.Formule :C47H62N8O4SCouleur et forme :SolidMasse moléculaire :835.11IPS-06061
IPS-06061 is an orally active molecular glue that forms a ternary complex with CRBN and KRASG12D, capable of degrading KRAS G12D, with a DC50 of less than 500 nM.Formule :C22H26O3Couleur et forme :SolidMasse moléculaire :338.44PROTAC KRAS G12C degrader-1
PROTAC KRAS G12C degrader-1, a cereblon-based degrader, promotes CRBN/KRAS G12C dimerization and facilitates the degradation of GFP-KRAS G12C in reporter cellsFormule :C50H54ClFN8O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :917.47MEK/RAF-IN-1
MEK/RAF-IN-1 (Compound 16b) serves as an inhibitor targeting both MEK and RAF, demonstrating potent efficacy with IC 50 values reported at 28 nM for MEK1, and 3 nM for both BRAF and BRAFV600E. This compound exhibits significant antitumor capabilities, effectively curbing cell proliferation in vitro in MIA PaCa-2 (G12C KRAS), HCT116 (G13D KRAS), and C26 (G12D KRAS) cells. Furthermore, MEK/RAF-IN-1 significantly restricts tumor growth in xenograft mouse models employed in the study of colorectal cancer.Formule :C28H29F3N6O5SCouleur et forme :SolidMasse moléculaire :618.63RTIL 13
CAS :RTIL 13 inhibits dynamin GTPase (IC50: 2.3 μM), targets its lipid binding domain, and suppresses endocytosis (IC50: 9.3 & 7.1 μM).Formule :C30H55BrN2O3Couleur et forme :SolidMasse moléculaire :571.685ADT-007
CAS :ADT-007 is a pan-RAS inhibitor with potent anticancer activity.Formule :C26H24FNO5Degré de pureté :97.75%Couleur et forme :SoildMasse moléculaire :449.47Ref: TM-T85316
1mg47,00€5mg96,00€1mL*10mM (DMSO)104,00€10mg124,00€25mg200,00€50mg353,00€100mg602,00€200mg982,00€Cobimetinib (R-enantiomer)
CAS :Cobimetinib R-enantiomer is the less active R-enantiomer of Cobimetinib which is a selective MEK inhibitor.Formule :C21H21F3IN3O2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :531.318Rac1 Inhibitor W56
CAS :Peptide (45-60) blocks Rac1 binding with TrioN, GEF-H1, Tiam1 GEFs.Formule :C74H117N19O23SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :1671.93(RS)-G12Di-1
(RS)-G12Di-1 is a selective covalent inhibitor of K-Ras-G12D.Formule :C37H35FN6O4Couleur et forme :SolidMasse moléculaire :646.27038
